can semaglutide cause sleeplessness and Insomnia: What the Evidence Shows Is Insomnia a Side Effect

As mentioned earlier in the manuscript, previous studies on the animal models showed the anti-fibrotic effects of GLP-1RA in addition to their capability of stimulating the surfactant production

weight loss (Phase 2/3 peak) | ~15% | ~22% | ~24% | | FDA Status | Approved (Wegovy, Ozempic) | Approved (Zepbound, Mounjaro) | Phase 3 (2026) | | Dosing frequency | Weekly | Weekly | Weekly | The additional glucagon receptor agonism is believed to be responsible for retatrutide's greater metabolic rate increase and enhanced fat oxidation compared to dual agonists

CRediT authorship contribution statement Ahmed I

Based on standard FDA review timelines (12 months for priority review), approval is expected in 20262027